CRIS Current Research Information System

MANCINI, MANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.398
EU - Europa 2.257
AS - Asia 1.300
AF - Africa 189
SA - Sud America 9
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.159
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.386
GB - Regno Unito 624
CN - Cina 442
IT - Italia 355
SG - Singapore 333
SE - Svezia 332
DE - Germania 297
VN - Vietnam 297
IE - Irlanda 133
UA - Ucraina 128
IN - India 127
RU - Federazione Russa 93
TG - Togo 88
FR - Francia 83
EE - Estonia 53
ZA - Sudafrica 51
JO - Giordania 33
FI - Finlandia 32
BG - Bulgaria 30
CH - Svizzera 30
NG - Nigeria 23
CI - Costa d'Avorio 18
BE - Belgio 16
IR - Iran 13
CA - Canada 11
ID - Indonesia 11
NL - Olanda 11
GR - Grecia 10
JP - Giappone 10
CZ - Repubblica Ceca 8
TR - Turchia 8
SC - Seychelles 7
HK - Hong Kong 6
CL - Cile 4
LB - Libano 4
PL - Polonia 4
RO - Romania 4
UZ - Uzbekistan 4
AU - Australia 3
BR - Brasile 3
HR - Croazia 3
IQ - Iraq 3
KR - Corea 3
NO - Norvegia 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
DK - Danimarca 2
EC - Ecuador 2
AL - Albania 1
BD - Bangladesh 1
EG - Egitto 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
MD - Moldavia 1
MU - Mauritius 1
MX - Messico 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
Totale 7.159
Salva come PNG Salva come JPEG
Città #
Southend 576
Chandler 469
Fairfield 349
Singapore 305
Ashburn 238
Wilmington 193
Seattle 188
Woodbridge 170
Houston 165
Dong Ket 160
Princeton 138
Dublin 133
Cambridge 131
Ann Arbor 122
Lomé 88
Santa Clara 82
Boardman 81
Jacksonville 79
Bologna 70
Nanjing 60
Beijing 58
Westminster 58
Padova 52
Berlin 45
New York 40
Redmond 40
Amman 33
San Diego 31
Sofia 30
Helsinki 29
Medford 28
Bern 27
Shenyang 26
Jinan 25
Saint Petersburg 24
Abeokuta 23
Changsha 23
Milan 23
Hebei 21
Falls Church 20
Turin 20
Abidjan 18
Nanchang 18
Tianjin 17
Brussels 16
Florence 16
Bremen 15
Dearborn 15
Jiaxing 15
Norwalk 14
Mülheim 13
Zhengzhou 13
Des Moines 11
Guangzhou 11
Jakarta 11
Mountain View 10
Phoenix 10
Taizhou 10
Hangzhou 9
Rome 9
Toronto 9
Washington 9
Harbin 8
Ningbo 8
Kunming 7
Mahé 7
Olalla 7
Redwood City 7
Shanghai 7
Andover 6
Bühl 6
Frankfurt am Main 6
Fuzhou 6
Kuban 6
Los Angeles 6
Xi'an 6
Bareggio 5
Boydton 5
Hong Kong 5
Lanzhou 5
Tokyo 5
Verona 5
Dehradun 4
Faenza 4
Forlì 4
Francofonte 4
Haikou 4
London 4
Paris 4
Warsaw 4
Zanjan 4
Brescia 3
Castel Madama 3
Catania 3
Chengdu 3
Foshan 3
Lappeenranta 3
Modena 3
Mumbai 3
San Mateo 3
Totale 4.928
Salva come PNG Salva come JPEG
Nome #
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 210
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 199
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 178
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 166
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 165
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 162
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 155
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 148
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 140
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 140
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 138
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 137
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 130
Best practices in chronic myeloid leukemia monitoring and management 129
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 128
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 127
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 125
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 120
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 118
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 117
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 117
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 116
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 115
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 114
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 113
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 111
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 110
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 110
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 108
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 106
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 104
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 104
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 102
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 101
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 101
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 99
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 99
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 99
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 99
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 95
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 93
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. 93
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 93
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 92
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 89
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 88
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 87
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 87
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 86
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 86
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 85
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 83
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 83
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 82
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 82
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 82
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 80
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 78
Present and future of molecular monitoring in chronic myeloid leukaemia. 78
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 75
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 75
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 69
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 61
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 60
Systemic mastocytosis: Molecular landscape and implications for treatment 57
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? 55
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia 50
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 36
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 34
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 32
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 26
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 24
A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib 2
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 7.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.022
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.022
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020887 0 0 0 0 0 0 213 195 203 115 63 98
2020/2021895 157 66 16 34 11 51 26 57 83 41 49 304
2021/20221.273 138 25 78 83 117 77 28 87 57 85 250 248
2022/20231.640 185 263 88 197 119 128 59 73 281 41 133 73
2023/2024449 20 79 27 63 37 100 22 29 14 21 16 21
2024/2025862 47 273 152 118 201 71 0 0 0 0 0 0
Totale 7.340